BerGenBio to Participate in Carnegie Nordic Healthcare Seminar

BerGenBio ASA – Approval and publication of a prospectus supplement

BerGenBio’s Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

BerGenBio ASA: Invitation to fourth quarter 2023 results webcast

BerGenBio announces closure of EU-SolidAct bemcentinib study arm in hospitalized COVID-19 patients

BerGenBio to Present at DNB Nordic Healthcare Conference

BerGenBio Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA: Grant of share options